Company: MIRA
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001183
Chunk: 116

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 1A
Chunk 116
---
982,343)
  
    Adjustments
    to reconcile net loss to net cash from operations 

    Non-cash
    interest expense 
     -  
     3,456,294 
  
    Stock-based
    compensation expense 
     1,920,805  
     2,550,946 
  
    Non-cash warrant expense 
     -  
     1,832,388 
  
    Non-cash
    investor relations fees 
     -  
     250,000 
  
    Change
    in operating assets and liabilities: 

    Right
    of use lease, net 
     -  
     5,500 
  
    Prepaid
    expenses 
     189,073  
     (243,802)
  
    Other
    receivables 
     11,862  
     (11,862)
  
    Trade
    accounts payable and accrued expenses 
     184,785  
     (389,524)
  
    Related
    party accrued interest 
     (14,472) 
     - 
  
    Net
    cash used in operating activities 
    $(5,560,606) 
    $(4,532,403)

    Financing
    activities: 

    Deferred
    offering costs 
     -  
     143,427 
  
    Repayments
    under related party line of credit 
     -  
     (1,142,483)
  
    Advances
    from (to) affiliates 
     33,713  
     (69,152)
  
    Advances
    received from related party line of credit 
     -  
     2,147,920 
  
    Bayshore
    Trust short-swing disgorgement 
     148,703  
     - 
  
    Proceeds
    from sale of common stock, less offering costs 
     3,608,555  
     7,704,279 
  
    Net
    cash provided by financing activities 
    $3,790,971  
    $8,783,991 

    Net
    increase (decrease) in cash  
     (1,769,635) 
     4,251,588 
  
    Cash,
    beginning of year 
     4,602,566  
     350,978